CombiMatrix's CombiSNP Array for Prenatal Diagnosis Test Granted Approval by NY State Department of Health

CombiMatrix Corporation

today announced its SNP-based chromosomal microarray analysis (CMA) test for prenatal diagnosis, the CombiSNP Array for Prenatal Diagnosis, has received approval from the New York Department of Health (NYDOH) thus allowing the company to market the test in New York State. CMA uses chorionic villus sampling (CVS) and amniocentesis samples to detect chromosomal imbalances that are not detected by karyotyping. Studies have shown that approximately one in 17 women who have a pregnancy with fetal ultrasound abnormalities and a normal fetal karyotype will have a clinically significant chromosomal abnormality detected by CMA. The American College of Obstetrics and Gynecology (ACOG) recommends prenatal microarray analysis when major structural fetal abnormalities are identified by ultrasound. In addition, CMA is recommended for confirmation of positive non-invasive prenatal testing (NIPT) results in order to preclude false positive results that can accompany the NIPT. "With this approval, we now offer a more complete portfolio of prenatal testing services to physicians in the New York market," said Mark McDonough, President and Chief Executive Officer of CombiMatrix.